<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1239</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12758178</PubmedId>
            <Abstract>The protective efficacy of the influenza matrix protein epitope 58-66 (called M1), recognized in the context of human HLA-A2 molecules, was evaluated in a HLA-A2/K(b) transgenic mouse model of lethal influenza infection. Repeated subcutaneous immunizations with M1 increased the percentage of survival. This effect was mediated by T cells since protection was abolished following in vivo depletion of all T lymphocytes, CD8(+), or CD4(+) T cells. The survival correlated with the detection of memory CD8(+) splenocytes able to proliferate in vitro upon stimulation with M1 and to bind M1-loaded HLA-A2 dimers, as well as with M1-specific T cells in the lungs, which were directly cytotoxic to influenza-infected cells following influenza challenge. These results demonstrated for the first time that HLA-A2-restricted cytotoxic T cells specific for the major immunodominant influenza matrix epitope are protective against the infection. They encourage further in vivo evaluation of T cell epitopes recognized in the context of human MHC molecules.</Abstract>
            <ArticleYear>2003</ArticleYear>
            <ArticlePages>320-9</ArticlePages>
            <ArticleTitle>The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Plotnicky</LastName>
                    <ForeName>H</ForeName>
                </Author>
                <Author>
                    <LastName>Cyblat-Chanal</LastName>
                    <ForeName>D</ForeName>
                </Author>
                <Author>
                    <LastName>Aubry</LastName>
                    <ForeName>J-P</ForeName>
                </Author>
                <Author>
                    <LastName>Derouet</LastName>
                    <ForeName>F</ForeName>
                </Author>
                <Author>
                    <LastName>Klinguer-Hamour</LastName>
                    <ForeName>C</ForeName>
                </Author>
                <Author>
                    <LastName>Beck</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Bonnefoy</LastName>
                    <ForeName>J-Y</ForeName>
                </Author>
                <Author>
                    <LastName>Corvaïa</LastName>
                    <ForeName>N</ForeName>
                </Author>
            </Authors>
            <Affiliations>Centre d'Immunologie Pierre Fabre, 5, Av. Napoléon III, 74 164, St Julien en Genevois, France. helene.plotnicky@pierre-fabre.com.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;HLA-A2 Antigen;Immunodominant Epitopes;Influenza Vaccines;Viral Matrix Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Disease Models, Animal; Epitopes, T-Lymphocyte(immunology); Female; HLA-A2 Antigen(genetics; immunology); Humans; Immunodominant Epitopes(immunology); Immunologic Memory; Influenza A virus(immunology); Influenza Vaccines(immunology); Influenza, Human(prevention &amp; control); Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Transgenic; T-Lymphocytes, Cytotoxic(immunology); Viral Matrix Proteins(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>309</Volume>
                <Issue>2</Issue>
                <Title>Virology</Title>
                <Issn>1096-0341</Issn>
                <MedlineTa>Virology</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>M1 58-66</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GILGFVFTL</LinearSequence>
                        <StartingPosition>58</StartingPosition>
                        <EndingPosition>66</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03485.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11320</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and methods</LocationOfData>
                <EpitopeId>20354</EpitopeId>
                <ReferenceStartingPosition>58</ReferenceStartingPosition>
                <ReferenceEndingPosition>66</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>1031099</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000076</OrganismId>
                                <Sex>F</Sex>
                                <Age>7 to 8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GILGFVFTL</LinearSequence>
                                            <StartingPosition>58</StartingPosition>
                                            <EndingPosition>66</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03485.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M1 58-66</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>2 doses of 100 µg, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with the epitope mixed with 100 μg of the TTp30 helper T cell epitope NNFTVSFWLRVPKVSASHLEQ.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>M1 58-66</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GILGFVFTL</LinearSequence>
                                        <StartingPosition>58</StartingPosition>
                                        <EndingPosition>66</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03485.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1 and 4</LocationOfData>
                        <TCellId>1031079</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000076</OrganismId>
                                <Sex>F</Sex>
                                <Age>7 to 8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GILGFVFTL</LinearSequence>
                                            <StartingPosition>58</StartingPosition>
                                            <EndingPosition>66</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03485.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M1 58-66</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 100 µg, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized 1, 2, or 3 times with the epitope mixed with 100 μg of the TTp30 helper T cell epitope NNFTVSFWLRVPKVSASHLEQ.</ImmunizationComments>
                        </Immunization>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus (A/Puerto Rico/8/34(H1N1))</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>127</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Seventy percent of epitope immunized mice survived to day 15, whereas none of the mice immunized with a control peptide survived. Survival of mice was dependent on both CD4+ and CD8+ T cells, since all mice depleted of CD8+, CD4+ or both T cell subsets died within 13 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>1031214</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000076</OrganismId>
                                <Sex>F</Sex>
                                <Age>7 yo 8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GILGFVFTL</LinearSequence>
                                            <StartingPosition>58</StartingPosition>
                                            <EndingPosition>66</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03485.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M1 58-66</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 100 µg, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized 2 or 3 times with the epitope mixed with 100 μg of the TTp30 helper T cell epitope NNFTVSFWLRVPKVSASHLEQ.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus (A/Puerto Rico/8/34(H1N1))</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>1031190</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000076</OrganismId>
                                <Sex>F</Sex>
                                <Age>7 to 8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GILGFVFTL</LinearSequence>
                                            <StartingPosition>58</StartingPosition>
                                            <EndingPosition>66</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03485.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M1 58-66</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 100 µg, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized 1, 2, or 3 times with the epitope mixed with 100 μg of the TTp30 helper T cell epitope NNFTVSFWLRVPKVSASHLEQ.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>M1 58-66</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GILGFVFTL</LinearSequence>
                                        <StartingPosition>58</StartingPosition>
                                        <EndingPosition>66</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03485.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>2749043</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000076</OrganismId>
                                <Sex>F</Sex>
                                <Age>7 yo 8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GILGFVFTL</LinearSequence>
                                            <StartingPosition>58</StartingPosition>
                                            <EndingPosition>66</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03485.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11320</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M1 58-66</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 100 µg, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized 2 or 3 times with the epitope mixed with 100 μg of the TTp30 helper T cell epitope NNFTVSFWLRVPKVSASHLEQ.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GILGFVFTL</LinearSequence>
                                        <StartingPosition>58</StartingPosition>
                                        <EndingPosition>66</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03485.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11320</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>TTp30</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NNFTVSFWLRVPKVSASHLEQ</LinearSequence>
                        <StartingPosition>948</StartingPosition>
                        <EndingPosition>968</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P04958.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1513</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>45103</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The TTp30 peptide contains an immunodominant helper T cell epitope for both human and mouse.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>1031232</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000076</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>NNFTVSFWLRVPKVSASHLEQ</LinearSequence>
                                            <StartingPosition>948</StartingPosition>
                                            <EndingPosition>968</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P04958.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1513</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>TTp30</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>2 doses of 100 µg, administered at intervals of 3 weeks.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with the epitope mixed with the influenza A peptide M1 58 – 66 (GILGFVFTL).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>TTp30</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NNFTVSFWLRVPKVSASHLEQ</LinearSequence>
                                        <StartingPosition>948</StartingPosition>
                                        <EndingPosition>968</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P04958.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1513</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

